CS
SMMT icon

Candriam SCA’s Summit Therapeutics SMMT Stock Holding History

Candriam SCA’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.75M Sell
532,432
-8,230
-2% -$146K 0.03% 314
2026
Q1 		$10.3M Hold
540,662
– – 0.05% 278
2025
Q4 		$9.46M Buy
540,662
+26,899
+5% +$506K 0.05% 278
2025
Q3 		$10.6M Hold
513,763
– – 0.06% 265
2025
Q2 		$10.9M Sell
513,763
-324,755
-39% -$7.41M 0.06% 242
2025
Q1 		$16.2M Sell
838,518
-4,033
-0.5% -$80.9K 0.1% 183
2024
Q4 		$15M Sell
842,551
-7,852
-0.9% -$152K 0.09% 209
2024
Q3 		$18.6M Buy
+850,403
New +$11.9M 0.11% 191

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Candriam SCA's SMMT Position: Q2 2026 in Review

Candriam SCA reduced its Summit Therapeutics (SMMT) stake by 1.5% in Q2 2026, selling an estimated $146K and leaving 532,432 shares worth $7.75M. The position accounts for 0.03% of the portfolio, ranked #314.

Candriam SCA first reported a position in SMMT in Q3 2024 and has held it in 8 quarters since. The position peaked at $18.6M in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Candriam SCA held 532,432 shares of Summit Therapeutics worth $7.75M as of Q2 2026.
  • Candriam SCA sold 8,230 Summit Therapeutics shares in Q2 2026, an estimated $146K.
  • Summit Therapeutics made up 0.03% of Candriam SCA's portfolio in Q2 2026, its #314 holding.
  • Candriam SCA first reported a position in Summit Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Candriam SCA's Summit Therapeutics position peaked at $18.6M in Q3 2024.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.